Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Tomas Minarik"'
Autor:
Katarina Kalavska, Tomas Minarik, Barbora Vlkova, Denisa Manasova, Michaela Kubickova, Andrej Jurik, Jozef Mardiak, Jozef Sufliarsky, Peter Celec, Michal Mego
Publikováno v:
Journal of Ovarian Research, Vol 11, Iss 1, Pp 1-7 (2018)
Abstract Background Patients with ovarian cancer represent a heterogeneous population with a variable prognosis and response to chemotherapy. Plasma DNA has been shown to have a prognostic value in different types of cancer including ovarian carcinom
Externí odkaz:
https://doaj.org/article/42f7ee9abbfb47cd9bfcacf3bc65747d
Autor:
Michal Mego, Andrej Jurik, Barbora Vlková, Jozef Sufliarsky, Peter Celec, Jozef Mardiak, Michaela Kubickova, Denisa Manasova, Tomas Minarik, Katarina Kalavska
Publikováno v:
Journal of Ovarian Research, Vol 11, Iss 1, Pp 1-7 (2018)
Journal of Ovarian Research
Journal of Ovarian Research
Background Patients with ovarian cancer represent a heterogeneous population with a variable prognosis and response to chemotherapy. Plasma DNA has been shown to have a prognostic value in different types of cancer including ovarian carcinoma. Whethe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0dbcf9512fc0edfd0d387b398bc7607a
http://link.springer.com/article/10.1186/s13048-018-0459-z
http://link.springer.com/article/10.1186/s13048-018-0459-z
Autor:
Lucia Kocova, Milan Krkoska, Katarina Kalavska, Bohumil Niznansky, Oliver Sadovsky, Michal Mego, Peter Celec, Tibor Lengyel, Tomas Minarik, Denisa Manasova, Jozef Sufliarsky, Michaela Kubickova, Barbora Vlková, Igor Slezak, Jozef Mardiak, Andrej Jurik
Publikováno v:
Journal of Clinical Oncology. 35:e17092-e17092
e17092 Background: Patients with ovarian cancer represent a heterogeneous population with a variable prognosis and response to chemotherapy. Circulating tumor DNA has been shown to have a prognostic value in different types of cancer including ovaria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97addc0522ac2b681b9771265e7f6c36
https://doi.org/10.1200/jco.2017.35.15_suppl.e17092
https://doi.org/10.1200/jco.2017.35.15_suppl.e17092
Autor:
Sandro Pignata, Philipp Harter, Petronella B. Ottevanger, Alexander Reinthaller, Martin Oliver Sailer, Susanne Malander, Nikolaus de Gregorio, Nicoletta Colombo, Frédéric Goffin, Mansoor Raza Mirza, Florence Joly, Margarita Romeo, Jacobus Pfisterer, Olivier Tredan, Aristotelis Bamias, Michael Merger, Andreas du Bois, Tomas Minarik, Gunnar B. Kristensen, Rainer Kimmig
Publikováno v:
Journal of Clinical Oncology. 32:5556-5556
5556^ Background: N is an oral inhibitor of VEGFR, PDGFR, and FGFR. As reported earlier, in the AGO-OVAR12 trial, N compared to placebo (Pl), added to standard chemotherapy, significantly prolonged...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cec798c3d1c06771883121d5af9d8336
https://doi.org/10.1200/jco.2014.32.15_suppl.5556
https://doi.org/10.1200/jco.2014.32.15_suppl.5556
Autor:
James M. Reuben, Michal Mego, Juraj Pechan, Gabriela Sieberova, Gabriel Minarik, Jan Macuch, Jozef Sufliarsky, Veronika Svabova, Juraj Benca, Tomas Minarik, Z. Hlavata, Marian Karaba, Andrej Jurik, Jozef Mardiak, Tatiana Sedlackova, Eva Oravcova, Denisa Manasova, Paulina Gronesova
Publikováno v:
Journal of Clinical Oncology. 31:e22023-e22023
e22023 Background: CTCs are prognostic in breast cancer (BC) patients and represent a heterogeneous population of cells with different phenotypes and biological value. EMT gives rise to cells with stem cell-like properties with increased chemotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::37ff5410138831157077035eea3a26cc
https://doi.org/10.1200/jco.2013.31.15_suppl.e22023
https://doi.org/10.1200/jco.2013.31.15_suppl.e22023
Autor:
I. Koza, Tomas Minarik, Z. Hlavata, T. Salek, Jana Obertova, Zuzana Sycova-Mila, L. Bohunicky, Jozef Sufliarsky, Jozef Mardiak, Thalmeinerová Z, Michal Mego
Publikováno v:
Journal of Clinical Oncology. 23:3689-3689
3689 Background: The oral fluoropyrimidines have therapeutic advantages over intravenous 5-fluorouracil such as tumor selectivity and inhibition of resistance mechanisms. Capecitabine is an oral tu...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::29b423706bd1162bd74139aba00c2775
https://doi.org/10.1200/jco.2005.23.16_suppl.3689
https://doi.org/10.1200/jco.2005.23.16_suppl.3689
Autor:
Marian Karaba, Tomas Minarik, Michal Mego, Juraj Benca, Daniel Pindak, Dana Cholujova, Jozef Sufliarsky, Silvia Cingelova, Jozef Mardiak, Paulina Gronesova, Viera Labudova, Pavol Janega, Zuzana Cierna
Publikováno v:
ResearcherID
e22103 Background: Plasmacytokines and angiogenic factors (CAFs) seem to be promising biomarkers in breast cancer patients and are involved in tumor dissemination and progression. Infiltration of b...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97a689c34a0c8455f647a632136fc402
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000358036904494&KeyUID=WOS:000358036904494
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=ORCID&SrcApp=OrcidOrg&DestLinkType=FullRecord&DestApp=WOS_CPL&KeyUT=WOS:000358036904494&KeyUID=WOS:000358036904494
